Dr. Massimiliano Bianchi is the Founder, President, and Chief Executive Officer of Ulysses Neuroscience Limited. He holds a PhD in Psychopharmacology from the University of Nottingham (UK) and has over 20 years of international R&D and executive experience in neuropharmacology and neuroscience research, including leadership roles in major pharmaceutical companies and CROs such as GlaxoSmithKline (UK), MAPREG (France), and Transpharmation (Ireland).

Before founding Ulysses Neuroscience in 2019, Massimiliano led translational research teams focused on neuronal plasticity and cytoskeletal dynamics in brain disorders. He also holds academic appointments as Adjunct Assistant Professor at Trinity College Dublin and Adjunct Associate Professor at Maynooth University. Under his leadership, Ulysses has become a globally recognized CRO and partner in depression and psychedelics research, supporting biotech and pharmaceutical companies with integrated, biomarker-driven translational platforms that bridge preclinical and clinical development.

In recognition of his entrepreneurial and scientific leadership, Massimiliano received the Campus Company Founders Award in 2023 from Trinity College Dublin, acknowledging Ulysses Neuroscience as a new model in translational neuroscience—operating at the interface between patients, academic research, and the pharmaceutical industry. In 2025, he was also named Champion of Progress by the Loulou Foundation, recognizing his contribution to advancing research and innovation in rare neurodevelopmental disorders.

Massimiliano is an established scientific author with over 50 peer-reviewed publications and is named on multiple patents in the field of neuroscience and drug discovery. His work spans preclinical models, biomarkers, and translational neuroscience strategies that bridge fundamental research and clinical development.

Gianni Matera serves as Chief Operating Officer of Ulysses Neuroscience Limited, bringing strategic leadership and operational expertise to the development and scaling of the company’s neuroscience research platforms and CRO services. As COO, he plays a central role in business development, partnership strategy, and organizational growth. 

Gianni has a strong track record in managing high-growth scientific ventures and aligning R&D initiatives with commercial and translational objectives. Prior to joining Ulysses Neuroscience, his experience includes leadership roles involving capital growth and operational oversight in life sciences innovation (e.g., through investment and growth initiatives in neuroscience and biotech). 

His leadership has supported Ulysses Neuroscience in securing funding and developing global collaborations with pharmaceutical and biotech partners.

Dr. Enya Paschen is Head of Preclinical Neuropharmacology at Ulysses Neuroscience Limited, where she directs preclinical research integrating behavioural pharmacology, neuromodulation, and electrophysiology (EEG) to explore innovative treatment strategies for neurological disorders. 

Enya completed her PhD in Neuroscience at the Freiburg Medical Centre and Albert-Ludwigs University (Germany), focusing on the physiological and behavioral impacts of neuromodulation in epilepsy. Her research included optogenetic circuit mapping and intracranial EEG, contributing to the development of deep brain stimulation approaches in preclinical models. 

In her current role, Enya advances the company’s translational preclinical platforms, emphasizing experimental models that closely reflect patient-relevant neurobiology. She is co-author on multiple scientific publications involving preclinical neuropharmacology and neuromodulatory strategies.

Dr. Connor Maltby is Head of Translational Medicine at Ulysses Neuroscience Limited. Connor earned his PhD in neuroscience-related research and subsequently completed postdoctoral research at the University of Michigan Medical School (USA), where he focused on genetically inherited movement disorders and intellectual disability using human stem cell–derived neuronal models. 

At Ulysses Neuroscience, Connor leads efforts to identify and validate new biomarkers, pharmacological targets, and genetic modifiers of rare and neurodevelopmental disorders in a translational, patient-centric context. His work bridges fundamental cellular biology with clinical relevance, advancing biomarker strategies that enhance drug discovery and therapeutic profiling. 

Connor’s scientific contributions include publications in peer-reviewed journals focused on synaptic plasticity and stem cell–based translational models. He is actively involved in cross-disciplinary neuroscience research initiatives that integrate cellular and clinical endpoints.